

---

**THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION**

---

**If you are in any doubt** as to any aspect of this circular or as to the action to be taken, you should consult your licensed securities dealer, bank manager, solicitor, professional accountant or other professional adviser.

**If you have sold or transferred** all your shares in Shandong Weigao Group Medical Polymer Company Limited, you should at once hand this circular and the enclosed proxy form and reply slip to the purchaser or transferee or to the bank or licensed securities dealer or other agent through whom the sale or transfer was effected for transmission to the purchaser or transferee.

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular.

---

**WEGO 威高**

山東威高集團醫用高分子製品股份有限公司

**Shandong Weigao Group Medical Polymer Company Limited \***

*(a joint stock limited company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 1066)**

**(1) SEVEN YEARS GREEN BOND AND  
FIVE YEARS LONG TERM LOAN FACILITIES  
(2) NOTICE OF SPECIAL GENERAL MEETING**

---

The notice convening the Special General Meeting of the Company to be held at 2/F, 18 Xingshan Road, Torch Hi-tech Science Park, Weihai, Shandong Province, the People's Republic of China (the "PRC") on 9:00 a.m., on Monday, 8 June 2020 are set out on pages 14 to 16 of this circular.

Whether or not you are able to attend the special general meeting, you are strongly urged to complete and sign the enclosed forms of proxy in accordance with the instructions printed thereon and please return it to the Company's H Share registrar, Tricor Standard Limited, Level 54, Hopewell Centre, 183 Queen's Road East, Hong Kong as soon as possible but in any event not later than 24 hours before the time appointed for the holding of the relevant meeting or any adjourned meeting (as the case may be). Completion and return of the form of proxy will not preclude you from attending and voting in person at the meeting or any adjourned meeting should you so wish.

21 April 2020

\* *For identification purpose only*

---

## CONTENTS

---

	<i>Page</i>
<b>DEFINITIONS</b> .....	1
<b>LETTER FROM THE BOARD</b> .....	3
SPECIAL GENERAL MEETING AND CLOSURE OF REGISTER OF MEMBERS .....	6
VOTING BY POLL .....	7
RECOMMENDATION .....	8
ADDITIONAL INFORMATION .....	8
<b>APPENDIX I – GENERAL INFORMATION</b> .....	9
<b>NOTICE OF SPECIAL GENERAL MEETING</b> .....	14

---

## DEFINITIONS

---

“Board”	the board of Directors
“Company”	Shandong Weigao Group Medical Polymer Company Limited* (山東威高集團醫用高分子製品股份有限公司)
“Directors”	the directors of the Company
“Green Bonds”	seven (7) years green bonds with a principal amount of RMB1,000,000,000.00
“H Shares”	the overseas-listed foreign invested shares in the share capital of the Company, with a nominal value of RMB0.10 each, which are held and traded in Hong Kong dollars
“Hong Kong”	the Hong Kong Special Administrative Region of the PRC
“IFC”	the International Finance Corporation, a member of the World Bank Group
“Latest Practicable Date”	17 April 2020, being the latest practicable date for ascertaining certain information contained in this circular prior to its publication
“Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange
“the Loan”	five (5) years long term loan with a principal amount of RMB500,000,000.00
“Loan Agreement”	the loan agreement entered into between the IFC and the Company dated 31 March 2020
“PRC”	the People’s Republic of China, excluding, for the purpose of this circular only, Hong Kong, the Macau Special Administrative Region of the PRC and Taiwan
“PRC Company Law”	the Company Law of the PRC

---

## DEFINITIONS

---

“RMB”	Renminbi, the lawful currency of the PRC
“Shareholder(s)”	the shareholder(s) of the Company
“Share Retention Agreement”	the share retention agreement dated 31 March 2020 among the Sponsor, the Company and IFC pursuant to which the Sponsor undertakes to maintain its shareholding in the Company and the Company undertakes to maintain its shareholding in the key subsidiaries
“Special General Meeting”	the special general meeting of the Company to be held at 2/F, 18 Xingshan Road, Torch Hi-tech Science Park, Weihai, Shandong Province, the PRC on Monday, 8 June 2020 at 9:00 a.m.
“Sponsor”	Weigao Holding Company Limited
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“Subscription Agreement”	the subscription agreement entered into between the IFC and the Company dated 31 March 2020
“Takeovers Code”	Hong Kong Code on Takeovers and Mergers
“HK\$”	Hong Kong dollars, the lawful currency of Hong Kong
“%”	per cent

---

LETTER FROM THE BOARD

---

**WEGO 威高**

山東威高集團醫用高分子製品股份有限公司  
**Shandong Weigao Group Medical Polymer Company Limited \***

*(a joint stock limited company incorporated in the People's Republic of China with limited liability)*

(Stock Code: 1066)

*Executive Directors:*

Mr. Zhang Hua Wei (*Chairman*)  
Mr. Long Jing (*Chief Executive Officer*)  
Mr. Wang Yi  
Mr. Gong Jian Bo

*Principal place of business in the PRC:*

18 Xingshan Road  
Torch Hi-tech Science Park  
Weihai  
Shandong Province  
the PRC

*Non-executive Directors:*

Mrs. Zhou Shu Hua

*Principal place of business  
in Hong Kong:*

*Independent non-executive Directors:*

Mr. Lo Wai Hung  
Mrs. Fu Ming Zhong  
Mrs. Wang Jin Xia

801 Chinachem Century Tower  
178 Gloucester Road  
Wanchai  
Hong Kong

21 April 2020

*To the Shareholders*

Dear Sir or Madam,

**(1) SEVEN YEARS GREEN BOND AND  
FIVE YEARS LONG-TERM LOAN FACILITIES  
(2) NOTICE OF SPECIAL GENERAL MEETING**

**INTRODUCTION**

The purpose of this circular is to provide you with information regarding the resolutions to be proposed at the Special General Meeting, to approve including but not limited to the entering of the Subscription Agreement and Loan Agreement between the Company and the IFC.

\* For identification purpose only

---

## LETTER FROM THE BOARD

---

This Circular is made in accordance with the requirement under articles of association of the Company. Refer to the announcement of the Company dated 31 March 2020, the Company entered into the Subscription Agreement and Loan Agreement with IFC, a member of the World Bank Group and the largest global development institution focused on the private sector in developing countries.

Pursuant to the Subscription Agreement, IFC has agreed, subject to the terms and conditions contained therein, to subscribe and pay for senior secured green bonds due 2027 in registered form in an aggregate principal amount of RMB1,000,000,000 (approximately HK\$1,093,223,000) to be created and issued by the Company.

### **Principal Terms of the Subscription Agreement (Seven Years Green Bond)**

Amount	RMB1,000,000,000.00.
Maturity Date	Single bullet redemption on 15 April 2027

Pursuant to the Loan Agreement, IFC has agreed, subject to the terms and conditions contained therein, to make available to the Company a loan in an aggregate principal amount of RMB500,000,000 (approximately HK\$546,611,000).

### **Principal Terms of the Loan Agreement (Five Years Long Term Loan Facilities)**

Amount	RMB500,000,000.00.
Maturity Date	Single bullet repayment on 15 April 2025

The Group hopes to develop its business objectives and creates shareholder/investor value, while at the same time protects the ecological environment by fully utilizing resources and minimizing the emission of pollutants during operation. The Group understands the importance of sustainable development and proactively shoulders the responsibility of protecting the environment and contributing to society while striving to provide professional medical assistance to doctors, nurses and patients and to promote the sustainable development of the entire medical industry worldwide. As a responsible and forward-looking enterprise, the Group is committed to balance the relationship between its operational measures and the environment, and continuously optimize operation governance, business strategy, environmental protection, talent cultivation and community investment to promote the sustainable development of the earth, human and business.

---

## LETTER FROM THE BOARD

---

The Company is the first healthcare company in China to issue a green bond. The Board considers that the Green Bonds will support the Company to implement measures to improve resource and energy efficiency, and to research and development and introduce the first Electron Beam sterilization (E-beam) process in China to displace toxic gas-based process (“**Ethylene Oxide**” or “**ETO**”) along its manufacturing process (the “**Project**”). The Project will play a key role in conserving water and energy, preventing environmental pollutions, as well as minimizing climate change footprint of the Company’s manufacturing base as it continues to expand its production capacity of affordable quality medical consumables. The Project will also lead to significant social impact to healthcare professionals and patients by protecting them from hazardous exposure to ETO which is the toxic residual gas left in medical supplies/devices after gas-based sterilization process.

In addition to water conservation measures introduced by Wego, The Green Bond proceeds will support the Group’s wastewater treatment facility. The treatment facility will focus on the domestic wastewaters generated from the Group and the effluent will be 100% reused for landscaping or irrigation.

Wego’s Green Bond will support a comprehensive list of energy and resource efficiency projects. It ranges from energy efficiency retrofit of technologies in its workshops, renewable energy generation facilities, EPC energy performance contracting, waste heat recovery and plastics-use efficiency improvement. The proposed Green Bond projects are expected to contribute the Climate Change Mitigation by reducing approximately 53,000 tCO<sub>2</sub>e per year.

The Loan will be applied to finance the increase in the Company’s and/or its subsidiaries’ production of single-use medical devices. The Company shall repay the Loan in one lump sum on 15 April 2025.

The Sponsor, the Company and IFC entered into a Share Retention Agreement on 31 March 2020. Under the Share Retention Agreement, so long as the Company’s right to request the subscription of the Green Bonds or the disbursement of the Loan is in force or any amount is outstanding under the Green Bonds and the Loan, the Sponsor shall maintain directly or indirectly not less than 35 per cent (35%) of the legal and beneficial ownership of the equity interests in the Company. The Sponsor’s breach of the Share Retention Agreement constitutes an event of default under the Subscription Agreement and the Loan Agreement, upon which the Green Bonds and the Loan may be accelerated. As at the date of this Circular, the Sponsor holds 2,159,755,676 shares in the Company, representing 47.76% of the total issued share capital in the Company.

Under the articles of association of the Company, the Company is required to obtain shareholders’ approval by special resolutions in a general meeting for issuance of bonds.

---

## LETTER FROM THE BOARD

---

Special resolutions will be proposed at the Special General Meeting to enter the Subscription Agreement and the Loan Agreement between the Company and the IFC, details of which are set out in the notice of the Special General Meeting.

An explanatory statement giving certain information is set out in the Appendix to this circular.

### **SPECIAL GENERAL MEETING AND CLOSURE OF REGISTER OF MEMBERS**

The register of members of the Company will be closed from Saturday, 9 May 2020 to Monday, 8 June 2020 (both days inclusive), for the purpose of determining shareholders' entitlement to attend the forthcoming special general meeting (the "Special General Meeting"), during which period no transfer of shares of the Company will be registered. In order to qualify for attending the Special General Meeting, shareholders should ensure that all transfer documents, accompanied by the relevant share certificates, are lodged with the Company's H share registrar, Tricor Standard Limited at Level 54, Hopewell Centre, 183 Queen's Road East, Hong Kong, for registration no later than 4:30 p.m. on Friday, 8 May 2020.

#### **In order to qualify for attending the Special General Meeting:–**

Latest time to lodge in the transfer instrument accompanied by the share certificates	4:30 p.m., Friday, 8 May, 2020
Closure of register of members of the Company for attendance of the SGM	Saturday, 9 May 2020 to Monday, 8 June 2020
Latest time to lodge in the reply slip	4:30 p.m., Monday, 18 May 2020
Date of SGM	Monday, 8 June 2020

### **SPECIAL GENERAL MEETING**

At the Special General Meeting, resolutions will be proposed to approve the entering of the Subscription Agreement and the Loan Agreement. The notice convening the Special General Meeting at which the resolutions mentioned above will be proposed are set out on pages 14 to 16 to this circular.



---

## LETTER FROM THE BOARD

---

The proxy form for use at the Special General Meeting is enclosed. Whether or not you are able to attend the SGM, you are strongly urged to complete and sign the enclosed form of proxy in accordance with the instructions printed thereon. For holders of H Shares, please return it to the Company's H Share registrar, Tricor Standard Limited, Level 54 Floor, Hopewell Centre, 183 Queen's Road East, Hong Kong, as soon as possible but in any event not later than 24 hours before the time appointed for the holding of the meeting or any adjourned meeting (as the case may be). Completion and return of the form of proxy will not preclude you from attending and voting in person at the meeting or any adjourned meeting should you so wish.

The Special General Meeting will be held at 9:00 a.m. on Monday, 8 June 2020 at 2/F, 18 Xingshan Road, Torch Hi-tech Science Park, Weihai, Shandong, the PRC to approve the Subscription Agreement and the Loan Agreement.

The relevant notice of the Special General Meeting is set out on pages 14 to 16 to this circular.

Proxy form for use at the Special General Meeting and reply slip is enclosed with this circular and are also published on the websites of the Hong Kong Stock Exchange (<http://www.hkexnews.hk>) and the Company (<http://www.weigaogroup.com>). Whether or not you are able to attend the meeting in person, you are requested to complete and return the proxy form in accordance with the instructions printed thereon and return it to the Company's H Share registrar, Tricor Standard Limited, at Level 54, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong, not less than 24 hours before the time fixed for holding the Special General Meeting or any adjournment thereof (as the case may be).

Completion and delivery of the proxy form will not preclude you from attending and voting in person at the meeting or any adjournment thereof (as the case may be) if you so wish.

If you intend to attend the Special General Meeting in person or by proxy, you should also complete and return the reply slip to the Company in person, by post or by fax on or before 4:30 p.m. on Monday, 18 May 2020 in accordance with the instructions printed thereon.

### **VOTING BY POLL**

In accordance with Rule 13.39(4) of the Listing Rules, any vote of shareholders at a general meeting must be taken by poll. As such, the resolutions set out in the notice convening the Special General Meeting, for will be voted by poll.

---

## LETTER FROM THE BOARD

---

### RECOMMENDATION

The Directors consider that the resolutions to be put before the Special General Meeting are in the best interests of the Company and the Shareholders as a whole. Accordingly, the Directors recommend that the Shareholders to vote in favour of all the aforesaid resolutions to be proposed at the Special General Meeting.

### ADDITIONAL INFORMATION

Your attention is drawn to the additional information set out in the Appendix to this circular.

By Order of the Board  
**Shandong Weigao Group Medical Polymer Company Limited**  
**Zhang Hua Wei**  
*Chairman*

## 1. RESPONSIBILITY STATEMENT

This circular, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief, the information contained in this circular is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this circular misleading.

## 2. DISCLOSURE OF INTERESTS

### (a) Interests and short positions of the Directors and the chief executives in the share capital and associated corporations of the Company

As at the Latest Practicable Date, the interests or short positions of the Directors and the chief executives in the Shares, underlying Shares or debentures of the Company or any of its associated corporation (within the meaning of Part XV of the SFO) which will have to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which he is taken or deemed to have under such provisions of the SFO) or which will be required, pursuant to section 352 of the SFO, to be recorded in the register referred to therein or which will be required to be notified to the Company and the Stock Exchange pursuant to the Model Code for Securities Transactions by Directors of Listed Companies contained in the Listing Rules (the “**Model Code**”), will be as follows:

#### (i) Long positions in the Shares of the Company

Director	Nature of interest (long position)	Number of Shares	Approximate percentage of shareholding (%)
Mr. Zhang Hua Wei	Beneficial interest	32,400,000	0.72
Mr. Wang Yi	Beneficial interest	23,400,000	0.52
Mrs. Zhou Shu Hua	Beneficial interest	15,300,000	0.34

Notes:

- (1) Mr. Chen Lin, son of Mr. Chen Xue Li, a son of Mr. Chen Xue Li, a director of Weigao Holding Company Limited is holding 196,000 H Shares, representing 0.004% of the issue share capital of the Company.

(ii) *Long positions in the registered capital of 威高集團有限公司 (Weigao Holding Company Limited), the holding company*

Name of shareholder	Capacity	Amount of registered capital	Approximate percentage of the registered capital of Weigao Holding
Weihai Weigao International Medical Investment Holding Company Limited* (Note)	Registered owner	1,078,000,000	89.83%
Mr. Chen Xue Li	Beneficial owner	69,540,000	5.79%
Mr. Zhang Hua Wei	Beneficial owner	21,960,000	1.83%
Mrs. Zhou Shu Hua	Beneficial owner	12,200,000	1.02%
Mr. Wang Yi	Beneficial owner	4,880,000	0.41%

Note: 威海威高國際醫療投資控股有限公司 (Weihai Weigao International Medical Investment Holding Company Limited\*) is owned as to 55.89% by Mr. Chen Xue Li, 18.00% by Mr. Zhang Hua Wei, 10.00% by Mrs. Zhou Shu Hua, 5.11% by Mr. Wang Yi and 8.00% by Mr. Chen Lin.

Save as disclosed above, as at the Latest Practicable Date, none of the Directors and chief executive of the Company or any of their spouses or children under the age of 18 was interested, or was deemed to be interested in the long and short positions in the Shares, underlying Shares and debentures of the Company or any of its holding company, subsidiaries or other associated corporation (within the meaning of Part XV of the SFO) which were required, pursuant to Section 352 of the SFO, to be entered in the register referred to therein; or were required pursuant to the Model Code to be notified to the Company and the Stock Exchange. At no time had the Company or any of its holding company or subsidiaries been participated in any arrangements to enable the Directors or chief executive (including their spouses or children under the age of eighteen) of the Company to acquire any interests and short positions of Shares or underlying Shares or debentures of the Company or any of its associated corporation (within the meaning of Part XV of the SFO).

**(b) Interests and short positions of substantial Shareholders and other parties in the Shares and underlying Shares of the Company**

As at the Latest Practicable Date, other than the interests and short positions of certain directors and chief executives as disclosed under the paragraph above, the interests and short positions of persons in the Shares and underlying Shares of the Company which would fall to be disclosed to the Company under the provisions of Divisions 2 and 3 of Part XV of the SFO or, who is, directly or indirectly, interested in 5% or more of the nominal value of any class of share capital carrying rights to vote in all circumstances at general meetings of any other members of the Group, or substantial shareholders as recorded in the register of substantial shareholder required to be kept by the Company under section 336 of the SFO were as follows:

Shareholder	Nature of interest	Number of Shares	Approximate percentage of shareholding (%)
Weigao Holding ( <i>Note</i> )	Beneficial interest (Long position)	2,159,755,676	47.76

*Note:* Weigao Holding directly holds 2,159,755,676 Shares. Weigao Holding is 89.83% controlled by 威海威高國際醫療投資控股有限公司, which in turn is 55.89% controlled by Mr. Chen Xueli

Save as disclosed above, as at the Latest Practicable Date, none of the Directors or chief executives of the Company had an interest or short position in the Shares or underlying Shares of the Company which would fall to be disclosed to the Company under the provisions of Divisions 2 and 3 of Part XV of the SFO or, who is, directly or indirectly, interested in 5% or more of the nominal value of any class of share capital carrying rights to vote in all circumstances at general meetings of any other members of the Group, or any other substantial shareholders whose interests or short positions were recorded in the register required to be kept by the Company under section 336 of the SFO.

**3. SERVICE AGREEMENTS**

As at the Latest Practicable Date, none of the Directors had entered or was proposing to enter into a service agreement with any member of the Group which is not determinable by the Group within one year without payment of compensation, other than statutory compensation.

**4. MATERIAL ADVERSE CHANGE**

As at the Latest Practicable Date, the Directors are not aware of any material adverse change in the financial or trading position of the Group since 31 December 2019, being the date to which the latest published financial statements of the Company were made up.

**5. COMPETING INTEREST**

As at the Latest Practicable Date, none of the Directors and their associates was interested in any business apart from the business of the Group, which competes or is likely to compete, either directly or indirectly, with that of the Group.

**6. INTEREST OF DIRECTORS**

As at the Latest Practicable Date, none of the Directors had any direct or indirect interest in any assets which have been acquired or disposed of by, or leased to, or which are proposed to be acquired or disposed of by, or leased to, the Company or any of its subsidiaries since 31 December 2019, being the date to which the latest published accounts of the Company were made up.

As at the Latest Practicable Date, there is no other contract or arrangement subsisting at the Latest Practicable Date in which any of the Directors is materially interested and which is significant in relation to the business of the Group.

**7. LITIGATION**

So far as the Company is aware, as at the Latest Practicable Date, no member of the Group was engaged in any litigation or arbitration of material importance and there is no litigation or claim of material importance known to the Directors pending or threatened by or against any member of the Group.

**8. DOCUMENTS AVAILABLE FOR INSPECTION**

Copies of the following documents will be available for inspection during normal business hours (Saturdays and public holidays excepted) at 801 Chinachem Century Tower, 178 Gloucester Road, Wanchai, Hong Kong from the date of this circular up to and including the date which is 14 days from the date of this circular:

- (a) the Subscription Agreement;
- (b) the Loan Agreement;

- (c) the Share Retention Agreement; and
- (d) this circular.

**9. MISCELLANEOUS**

- (a) none of the Directors had any direct or indirect interest in any assets which had been acquired or disposed of by or leased to any member of the Group or proposed to be so acquired, disposed of by or leased to any member of the Group since 31 December 2019, being the date to which the latest published audited accounts of the Company were made up, and up to the Latest Practicable Date.
- (b) Save as disclosed above, none of the Directors was materially interested in any contract or arrangement entered into by the Company or any of its subsidiaries which contract or arrangement is subsisting at the Latest Practicable Date and which is significant in relation to the business of the Group.
- (c) The company secretary of the Company is Mrs. Wong Miu Ling, Phillis, FCIS and FCS.
- (d) The Hong Kong share registrar and transfer office is Tricor Standard Limited of Level 54, Hopewell Centre 183 Queen's Road East Wanchai Hong Kong.
- (e) In the event of inconsistency, the English language text of this circular shall prevail over the Chinese language text.

---

## NOTICE OF SPECIAL GENERAL MEETING

---

# **WEGO 威高**

山東威高集團醫用高分子製品股份有限公司  
**Shandong Weigao Group Medical Polymer Company Limited \***

*(a joint stock limited company incorporated in the People's Republic of China with limited liability)*

(Stock Code: 1066)

### NOTICE OF SPECIAL GENERAL MEETING

**NOTICE IS HEREBY GIVEN** that the special general meeting (the “SGM”) of Shandong Weigao Group Medical Polymer Company Limited\* (山東威高集團醫用高分子製品股份有限公司) (the “**Company**”) will be held at 2/F, 18 Xingshan Road, Torch Hi-tech Science Park, Weihai, Shandong Province, the PRC at 9:00 a.m. on Monday, 8 June 2020 to consider and, if though fit, pass the following resolutions:

#### SPECIAL RESOLUTIONS

The purpose of the Special General Meeting is to consider the following special resolutions:

1. **THAT** the board be and is hereby authorized to approve, execute and do or procure to be executed and done, all documents and things as it may consider necessary in connection with the entering of:–
  - i. the Subscription Agreement between the Company and the IFC;
  - ii. the Loan Agreement between the Company and the IFC; and
  - iii. the Share Retention Agreement among the Sponsor, the Company and the IFC.

\* For identification purpose only



---

## NOTICE OF SPECIAL GENERAL MEETING

---

2. **THAT** one of the directors of the Company be and is hereby authorized:
  - i. to approve, execute and do or procure to be executed and done, all such documents and things as it may consider necessary in connection with the Subscription Agreement, the Loan Agreement and the Share Retention Agreement; and
  - ii. to submit to authority for approval or filing of any relevant document.
  
3. **THAT** to ratify, confirm and approve any action taken by any director prior to the date of this SGM in connection with the entering of:
  - i. the Subscription Agreement between the Company and the IFC;
  - ii. the Loan Agreement between the Company and the IFC; and
  - iii. the Share Retention Agreement among the Sponsor, the Company and the IFC.

By Order of the Board  
**Shandong Weigao Group Medical Polymer Company Limited**  
**Zhang Hua Wei**  
*Chairman*

Weihai, the PRC  
21 April 2020

*As at the date of this notice, the Board comprises:*

Mr. Zhang Hua Wei (*Executive Director*)  
Mr. Long Jing (*Executive Director*)  
Mr. Wang Yi (*Executive Director*)  
Mr. Gong Jian Bo (*Executive Director*)  
Mrs. Zhou Shu Hua (*Non-executive Director*)  
Mr. Lo Wai Hung (*Independent non-executive Director*)  
Mrs. Fu Ming Zhong (*Independent non-executive Director*)  
Mrs. Wang Jin Xia (*Independent non-executive Director*)

---

## NOTICE OF SPECIAL GENERAL MEETING

---

*Notes:*

1. For the purpose of determining who may attend the SGM to be held on Monday, 8 June 2020, the register of holders of H Shares of the Company will be closed from Saturday, 9 May 2020 to Monday, 8 June 2020 (both dates inclusive), during which no transfer of H Shares will be registered. In order to qualify for entitlement to attending and voting in the SGM, all transfers of H Shares accompanied by the relevant share certificates and transfer forms must be lodged with the Company's H Share registrar, Tricor Standard Limited for registration not later than 4:30 p.m. on Friday, 8 May 2020.

The address of Tricor Standard Limited is as follows:

Level 54  
Hopewell Centre  
183 Queen's Road East  
Hong Kong  
Fax: (852) 2810 8185

2. In accordance with the Listing Rules, any vote of shareholders at a general meeting must be taken by poll. As such, the resolutions set out in the notice of SGM will be voted by poll. Results of the poll voting will be published on the Company's website at [www.weigaogroup.com](http://www.weigaogroup.com) and the website of Hong Kong Exchanges and Clearing Limited at [www.hkexnews.hk](http://www.hkexnews.hk) after the SGM.
3. Any shareholder entitled to attend and vote at the SGM convened by the above notice is entitled to appoint one or more proxies to attend and vote instead of him/her. A proxy need not be a shareholder of the Company.
4. In order to be valid, the instrument appointing a proxy together with the power of attorney or other authority, if any, under which it is signed, or a notarially certified copy of such power of attorney or authority, must be completed and deposited at the Company's H Share registrar, Tricor Standard Limited or the registered office of the Company, at least 24 hours before the SGM or any adjourned meeting thereof. The Company's registered office is located at 18 Xingshan Road, Torch Hi-tech Science Park, Weihai, Shandong Province, the PRC (Fax no. (86) 631 5620555). The Company's H Share registrar, Tricor Standard Limited, is located at Level 54, Hopewell Centre, 183 Queen's Road East, Hong Kong (Fax no. (852) 2810 8185).
5. Completion and return of a proxy form will not preclude you from attending and voting at the SGM or any adjourned meeting thereof if you so wish.
6. In case of joint shareholdings, the vote of the senior joint shareholder who tenders a vote, whether in person or by proxy, will be accepted to the exclusion of the votes of the other joint shareholder(s) and for this purpose seniority will be determined by the order in which the names stand in the register of members of the Company in respect of the joint shareholding.
7. Shareholders who intend to attend the SGM in person or by proxy should return the reply slip for the SGM to the registered office of the Company or the principal place of business of the Company in Hong Kong by hand, by post or by fax on or before Monday, 18 May 2020. The Company's registered office is located at 18 Xingshan Road, Torch Hi-tech Science Park, Weihai, Shandong Province, the PRC (Fax no. (86) 631 5620555). The principal place of business of the Company in Hong Kong, is located at 801 Chinachem Century Tower, 178 Gloucester Road, Wanchai, Hong Kong (Fax no. (852) 2838 1870).
8. The SGM is expected to last for about half a day. Shareholders who attend the meeting in person or by proxy shall bear their own travelling and accommodation expenses. Shareholders or their proxies shall produce their identity documents when attending the SGM.